Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Theravance Biopharma, Inc.NASDAQ: TBPH

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables broadly unchanged from a year ago

Net receivables stood at $15.58M at the end of Q1 FY2026, up 1.5% from a year earlier and down 83.7% from the prior quarter. Over 3 fiscal years it compounded at +78.5% a year.

Context

  • Net receivables amounted to 3.3% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +1.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.58M-83.7% QoQ
Last fiscal yearDec 2025
$95.54M+39.6% YoY
Year agoMar 2025
$15.35M+1.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year+39.6%——
3-year CAGR+78.5%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
95.54M USD
Year-over-year change
+39.6%
4-year CAGR
+13.5%

Net Receivables vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +1.5% is the 3rd highest of 7, against a peer median of -36.7%.
  • Net receivables amounts to 3.3% of total assets for TBPH, versus a peer median of 0.4%.
TBPH Competitors
Net Receivables for TBPH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GERNGeron CorporationMar 2026$44.1M USD+29.8%+131.9%8.3%
TBPHTheravance Biopharma, Inc.Mar 2026$15.58M USD+1.5%+78.5%3.3%
VALNValneva SEMar 2026€10.14M EUR-69.7%+5.2%2.7%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$4.61M USD+227.3%-15.6%0.6%
REPLReplimune Group, Inc.Dec 2025$2.96M USD-3.6%+6.8%0.9%
LENZLENZ Therapeutics, Inc.Mar 2026$343K USD——0.1%
VIRVir Biotechnology, Inc.Mar 2026$0 USD——0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$0 USD-100.0%—0.0%
TYRATyra Biosciences, Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding TBPH) —-36.7%+6.0%0.4%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents89.96M298.17M39.55M37.8M167.81M
Short-term Investments83.51M29.31M62.88M50.55M147.55M
Net Receivables57.6M16.79M17.47M68.44M95.54M
Inventory00000
Other Current Assets8.56M7.68M11.6M4.2M7.56M
Total Current Assets249.87M353.46M133.54M161.07M418.46M
Property, Plant & Equipment (Net)53.35M52M45.36M35.77M30.27M
Goodwill00000
Intangible Assets00000
Long-term Investments68.37M00014.35M
Tax Assets00000
Other Non-current Assets3.23M201.94M203.1M157.32M22.5M
Total Non-current Assets124.95M253.94M248.46M193.09M67.11M
Total Assets374.82M607.4M382M354.16M485.57M
Account Payables3.1M1.55M1.52M2.24M2.57M
Short-term Debt17.44M00010.95M
Tax Payables0005.85M0
Deferred Revenue98K24K000
Other Current Liabilities25.15M(24K)12.88M06.91M
Total Current Liabilities58.59M28.72M24.77M32.09M38.3M
Long-term Debt599.39M00032.8M
Deferred Tax Liabilities240K00085.68M
Deferred Revenue (Non-current)310K192K000
Other Non-current Liabilities2.18M91.29M99M107.42M313K
Total Non-current Liabilities654.81M136.89M144.24M146.53M150.55M
Total Liabilities713.39M165.6M169M178.62M188.85M
Common Stock1K1K001K
Retained Earnings(1.73B)(853.91M)(909.1M)(965.52M)(859.63M)
Accumulated OCI(0)(15K)(65K)7K61K
Other Stockholders Equity00(0)(0)0
Minority Interest00000
Total Equity(338.57M)441.8M213M175.55M296.72M
Total Debt669.52M52.16M49.16M49.82M75.5M
Net Debt579.56M(246.01M)9.61M12.02M(92.31M)

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.